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Introduction 
IMPROVED UNDERSTANDING of osteoarthritis (OA) 
has helped facilitate the development of a number of 
new agents that appear able to inhibit cartilage 
degradation and slow or halt the progression of OA 
in animal models [1, 2]. Several of these drugs are 
now being considered for clinical trials in human 
OA [3-5]. This necessitates the development of 
reliable methodology for the detection of disease 
modifying activity in the human disease [6, 7]. The 
hip and knee joints are the two peripheral sites 
affected by OA which result in the main burden of 
pain and disability, so it is logical to concentrate 
trials of potential disease modifying agents on 
osteoarthritis of the hip or knee. 
Osteoarthritis is now regarded as a disease 
process that leads to changes in the structure 
and function of synovial joints. The main patient- 
related outcomes are pain and disability, leading 
to extensive use of health care resources, such 
as drugs, physical therapy and surgery. There 
are therefore three potential dimensions of OA that 
could be assessed to detect disease modifying 
drug activity: disease process measures (such as 
changes in molecular markers); imaging the 
structural changes in joints (such as radiographic 
progression); or the patient-related outcomes 
such as pain, disability and the need for surgical 
interventions. - 
It has recently been suggested that drugs used 
for the treatment of OA should be classified as 
quick or slow acting, and as symptomatic or 
disease modifying [8]. Symptomatic drug activity 
can be detected through measures of pain and the 
use of disease specific outcome measures uch as 
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the Lequesne or Western Ontario and McMaster 
Universities Osteoarthritis index (WOMAC) 
algofunctional indices [9, 10], whereas disease 
modifying activity requires an assessment of tour- 
phological change in the joint, such as inhibition 
of radiographic progression. However, there is 
no current consensus on the methodology that 
should be used for either clinical or radiographic 
assessments of outcome in hip and knee OA. 
Furthermore, the techniques that should be used to 
obtain the radiographs, or measure change from 
them, have not been agreed upon. In addition, there 
is a need for standardization f the methods used to 
record the clinical features of the disease, to obtain 
body fluid samples for molecular marker assays, and 
for alternative t chniques used to assess OA, such as 
magnetic resonance imaging (MRI). 
In April 1994, a consensus meeting was held 
in conjunction with the American Academy of 
Orthopaedic Surgeons, the National Institutes of 
Health and the World Health Organization (WHO). 
One aim of the meeting was the production of 
recommendations for a minimum set of standard 
methodologies that could be applied to all 
longitudinal clinical studies of hip or knee OA. 
The group considered both standard clinical and 
radiographic techniques, as well as emerging 
technologies, pecifically MRI, molecular markers 
and arthroscopic assessments of cartilage damage. 
This paper summarizes ome of the outcomes of 
this meeting, with an emphasis on the consensus 
achieved with standard technologies. The full 
proceedings ofthe meeting are published elsewhere 
[11]. 
Characterization of  homogenous patient 
groups, and identification of  those at highest 
risk of rapid disease progression 
Hip and knee OA are heterogeneous conditions 
with variable outcomes. The intra-articular 
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distribution of the disorder (tibiofemoral or 
patellofemoral knee OA, for example) as well as 
some of the associations, uch as obesity, may affect 
the progression and outcome of OA. It was agreed 
that patients with overt inflammatory artropathies, 
and disorders uch as avascular necrosis, ochrono- 
sis, periarticular fractures or Paget's disease 
should be excluded from studies of OA progression 
and treatment, and that it is desirable to define 
as homogenous a patient group as possible for all 
clincial studies. 
Some specific patient groups may be particularly 
well suited to intervention studies, because of their 
high risk of relatively rapid progression. Examples 
might include obese women with unilateral knee 
OA, in whom both knee joints can be followed, and 
older subjects who have experienced major intra- 
articular trauma. The intra-articular distribution 
of disease should also be considered; for example, 
trials should not mix patients with tibiofemoral nd 
patellofemoral knee OA, rather they should be 
considered as separate disorders. Additionally, 
recent data suggests that certain methods, such as 
scintigraphy, or some molecular marker assays, 
might help differentiate hose at high or low risk of 
disease progression [12, 13]. Patient selection on 
this basis might affect he power of an intervention 
study. 
The identi f icat ion of  pat ients with OA for 
cl inical studies, and co l lect ion of  basel ine data 
Many different ways of defining the OA are 
used in clinical trials. The ACR classification 
criteria [14, 15] have helped introduce some measure 
of standardization, but they are not diagnostic 
criteria. The consensus of this group was that entry 
criteria for clinical studies should include symp- 
toms and/or radiographic hanges in the affected 
joint, depending on the defined purpose of the 
study. Pain is the most important symptom, but 
it is not yet clear what minimal frequency and 
severity of pain should be required for entry to 
either progression, or intervention studies. The 
suggested radiographic changes are as follows: for 
the hip, joint space narrowing of the superior and/or 
medial joint space, with at least one other feature of 
OA, such as osteophyte formation or subchondral 
bone changes, and for the knee, osteophyte 
formation in at least one compartment of the 
joint. 
The baseline data collected on patients entering 
studies of OA progression or intervention should 
include factors that might affect reporting of 
symptoms, as well as progression. The data should 
include: age, gender, race, height and weight, 
Table I 
Suggested core data set to be collected for all clinical 
trials of progression or outcome of knee or hip OA 
Age, gender and race 
Height and weight (BMI) 
Symptomatic joint(s) 
Disease duration/date of any initiating event (e.g. injury) 
Date/nature ofany surgical intervention 
Current drug therapy 
Date/nature of last intra-articular injection (if any) 
Socio-economic status 
Psychosocial/general health status (e.g. SF 36) 
Functional status (e.g. Lequesne or WOMAC) 
socio-economic status, psychosocial status, func- 
tional status and the distribution of joints involved 
with OA. The nature and date of any event (such as 
joint trauma) that might have initiated the 0A 
should also be recorded. A suggested minimum core 
clinical data set that might be collected for all OA 
progression and outcome studies, and in conjunc- 
tion with any investigations to validate new imaging 
or biochemical techniques, is outlined in Table I. 
Clinical measures  used to assess  progress ion 
and outcome 
Ideally, all outcome studies of OA should use the 
same sensitive measures of change, so that different 
intervention strategies can be compared. The WHO 
currently recommends the use of the WOMAC or 
Lequesne algofunctional indices as primary clinical 
efficacy measures in hip and knee OA; both of these 
indices include a measure of activity-related and 
night pain, and a visual analogue pain scale should 
always be included in the assessment of OA. It is also 
suggested that joint specific change in pain and the 
physician and patient global assessments of change 
should be included in intervention studies. The 
inclusion of a lot of other clinical outcome measures 
is unlikely to be helpful, although the addition of 
a general health status measure, such as the SF 36 
[16], or other forms of functional assessment, may 
add useful information in long term outcome 
studies. 
Radiographic measures  of  progress ion 
It was agreed that at present, changes in 
radiographs remain the major outcome measure 
that should be used to assess morphological 
progression of 0A. However, it is vital that the 
techniques used to obtain and read the radiographs 
are standardized for multicentre or comparative 
studies. To this end, the methods described here 
require no special facilities, it is recommended that 
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all films should be obtained with fast screen cassette 
film, using a focus to film distance of 100 cm. 
PATIENT POSIT IONING 
Hip films may be obtained with the patient supine 
or standing. If the subject is standing, foot maps can 
be used to aid reproducibility of the positioning. 
If the subject is supine, the X-ray beam should be 
perpendicular to the table and centred on the 
superior aspect of the symphysis pubis, and the feet 
should be internally rotated (internal rotation 
probably generates a load on the articular surface; 
this may obviate the need for a weight-bearing film, 
although much more data are needed to define 
which views are superior [17]). More data are 
also needed to fully define the most appropriate 
views that should be taken of the knee joint. The 
most studied view of the tibiofemoral joint is the 
antero-posterior weight-bearing view of both knees 
in extension. However, partial flexion views may 
be of greater value, both for the detection of early 
changes and the assessment of progression [18]. 
These can be obtained by positioning the patient 
standing with the toes up against he edge of a film 
cassette and the knees bent to lie against it. The 
X-ray beam is directed at a 5 ° downward angle at a 
site midway between the popliteal spaces. As with 
the hip, foot maps can be used to aid reproducibility. 
Two views have been used for the patellofemoral 
joint, either the supine lateral view (which should 
be taken in a carefully standardized 40 ° flexion 
position) or the sunrise (sunset, axial or skyline) 
view usually taken in 40 ° of flexion (using a 
positioning wedge) with the patient supine and the 
X-ray beam parallel to the table. Data are needed to 
compare the relative value of these two views. 
being present or absent, and further work is needed 
to determine whether these features can also be 
reliably graded on a 0-3 scale. In addition, at both 
hip and knee joints, Kellgren and Lawrence grades 
[19] of overall severity, or appropriate modifications, 
can be recorded. In some studies, a global score of 
the change in overall severity of paired radiographs 
may also be of value. 
REPRODUCIBILITY AND QUALITY CONTROL 
Ideally radiographs should be read centrally, with 
one to three experts reading all films. There are 
advantages to blinding readers to sequence and 
clinical data, although for comparisons of change, 
films may need to be read together and this issue 
requires consideration within the needs of different 
studies. Quality and reproducibility can be verified 
with test-retest and intra-inter-reliability testing. 
Training and standardization can be assisted by the 
use of atlases [20, 21] and training. Each individual 
study should involve the use of a manual that clearly 
defines the methodology to be used. 
ADVANCED TECHNIQUES THAT CAN BE USED TO ASSESS 
RADIOGRAPHS 
Digitization of the images will aid the application 
of computerized methods for the assessment of 
X-rays, such as area of volume measurements of 
interbone distance or osteophytosis using edge 
detection programs. Other advances in X-radiogra- 
phy, such as micro-focal techniques, dual energy 
X-ray absorptiometry and micro CT may also be 
of value and aligning joints with the help of 
fluoroscopy may improve the reproducibility ofjoint 
space measurements [18]. 
RADIOGRAPHIC FEATURES TO BE RECORDED 
For the hip joint space narrowing should be 
recorded, both in millimetre measuresments of
interbone distance (measuring the narrowest point 
with a ruler or calipers) and by visual grading (0-3). 
Femoral osteophytes can be graded 0-3 and other 
features such as subchondral bone cysts and 
sclerosis, attrit ion and migration can be recorded as 
present or absent. Radiographic features of knee 
disease should be recorded separately for the 
medial, lateral and patellofemoral compartments. 
As with the hip, the narrowest point of the 
tibiofemoral joint space can be measured in 
millimetres, and both joint space narrowing and 
osteophytes can be graded 0-3 in all compartments. 
Other features, such as sclerosis, bony attrition, 
chondrocalcinosis and subluxation, can be noted as 
Collect ion of  body fluids for mo lecu lar  
marker  studies 
There is increasing interest in the use of 
molecular marker assays to study the disease 
processes involved in OA [22-24]. It will be essential 
to relate such marker assays to other measures of 
progression and outcome to further investigate 
their value and possible use as surrogate outcome 
measures in the future. A number of promising 
candidate assays have been identified, although at 
present none can be specifically recommended as
providing a measure of disease progression. 
Standardized methods for the collection and 
storage of samples will need to be used in 
multicentre and comparative studies of OA pro- 
gression and outcome. It was recommended that the 
urine specimens obtained should be the second void 
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Table II 
Suggested sample-centred data to be collected with any body fluid sampling for molecular marker 
assays for OA process~activity 
Patient identification and demography 
Date and time sample taken 
For synovial fluid: Total volume withdrawn 
Lavage or other special techniques used 
Site of venepuncture (if not antecubital vein, where?) 
First or subsequent morning void, or other time of spot sample 
Have guidelines for handling and storage been adhered to? (If no provide 
details) 
Temperature of storage of samples 
For plasma: 
For urine: 
For all: 
of the morning, clarified in a centrifuge within 4 h, 
and stored frozen in 25-ml aliquots in polypropylene 
tubes. For blood specimens, it was suggested that 
25 ml of fasting blood be collected in either heparin 
or EDTA tubes (depending on the specific marker 
assays of interest), centrifuged within 4 h and stored 
frozen in aliquots in polypropylene tubes. Synovial 
fluid samples present special problems. However, if 
there is sufficient volume available, it is again 
recommended that they are collected in heparin or 
EDTA containing tubes to prevent fibrin or clot 
formation, centrifuged at 3000g for 15 min. and 
aliquots stored frozen in Eppendorf type tubes. All 
samples hould be stored at -70 or -80°C, if possible, 
and it was recommended that a sample centred 
data set be collected with all samples (Table II), 
in addition to the core clinical data set needed 
in all studies of OA progression and outcome. 
Reference centres and standard samples may need 
to be made available in the future to help ensure 
the reproducibility and quality control of marker 
assays. All three body fluids should be collected 
whenever possible. 
Magnetic resonance imaging and arthroscopy 
Magnetic resonance imaging (MRI) and 
arthroscopy were considered to be among the most 
important emerging technologies, and of value in 
documenting both the morphological changes and 
(especially in the case of MRI) the processes 
involved in the evolution of OA [25-27]. In both 
cases, consideration was given to the need to 
carefully standardize and describe the technology 
to be used in any study, and to validate any scoring 
systems to be used. 
Both technologies are evolving fast, and are 
in need of extensive validation against existing 
methods, and by comparison with histopathological 
changes in joints. Until more data were available, it 
was not thought appropriate to provide specific 
recommendations for clinical studies, other than 
emphasizing the need for standard protocols and 
careful, full descriptions of any methods used. 
However, MRI protocols are available for the study 
of knee joints using standard hospital scanners 
[25, 26], and chondroscopy has been used suc- 
cessfully in some studies [27], indicating that 
when available, such technology is already able to 
contribute to the field. 
Conclusions 
The methodologies that might be used to assess 
the progression of OA, and the value of any 
interventions is emerging. The process leading to 
the recommendations outlined in this article needs 
to be an ongoing one, driven by new data as well as 
the needs of investigators and industry. 
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